CORRESP Filing
InMed Pharmaceuticals Inc.
Date: July 14, 2025 · CIK: 0001728328 · Accession: 0001213900-25-063685
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288594
Letter
INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St.
Vancouver, British Columbia, Canada
V6C 3E8
VIA EDGAR
July 14, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc.
Acceleration Request for Registration Statement on Form S-1
Filed July 9, 2025
File No. 333-288594
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to July 16, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151.
Sincerely,
INMED PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR July 14, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed July 9, 2025 File No. 333-288594 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to July 16, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable. If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151. Sincerely, INMED PHARMACEUTICALS INC. /s/ Eric A. Adams Eric A. Adams President and Chief Executive Officer cc: Netta Jagpal, InMed Pharmaceuticals Inc. Scott R. Saks, Norton Rose Fulbright US LLP Trevor Zeyl, Norton Rose Fulbright Canada LLP